4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Potent and selective p70S6 kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 17, 2009, Pages 5191-5194

  Bandarage, Upul ^a   Hare, Brian ^a   Parsons, Jonathan ^a   Pham, Ly ^a   Marhefka, Craig ^a   Bemis, Guy ^a   Tang, Qing ^a   Moody, Cameron Stuver ^a   Rodems, Steve ^a   Shah, Sundeep ^a   Adams, Chris ^b   Bravo, Jose ^b   Charonnet, Emmanuelle ^b   Savic, Vladimir ^b   Come, Jon H ^a   Green, Jeremy ^a  

^a VERTEX PHARMACEUTICALS   (United States)

^b BioFocus DPI   (United Kingdom)

Author keywords

1,2,5 Oxadiazole; 3 Aminofurazan; p70S6 Kinase; p70S6K

Indexed keywords

4 (BENZIMIDAZOL 2 YL) 1,2,5 OXADIAZOL 3 AMINE DERIVATIVE; CYCLIC AMP DEPENDENT PROTEIN KINASE; FURAZAN DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; MOLECULAR SCAFFOLD; PROTEIN KINASE INHIBITOR; RHO KINASE; S6 KINASE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITOR INTERACTION; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

BENZIMIDAZOLES; BINDING SITES; CATALYTIC DOMAIN; COMPUTER SIMULATION; CYCLIC AMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNITS; DRUG DESIGN; GLYCOGEN SYNTHASE KINASE 3; OXADIAZOLES; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 68349158679     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.022     Document Type: Article

References (14)

1. Thomas G. Biol. Res. 35 (2002) 305
2. Nobukini T., and Thomas G. Novartis Found. Symp. 262 (2004) 148
3. Harrington L.S., Findlay G.M., and Lamb R.F. Trends Biochem. Sci. 30 (2005) 35
4. Radimerski T., Montagne J., Hemmings-Mieszczak M., and Thomas G. Genes Dev. 16 (2002) 2627
5. Olesen P.H., Sorensen A.R., Urso B., Kurtzhals P., Bowler A.N., Ehrbar U., and Hansen B.F. J. Med. Chem. 46 (2003) 3333
6. Doe C., Bentley R., Behm D.J., Lafferty R., Stavenger R., Jung D., Bamford M., Panchal T., Grygielko E., Wright L.L., Smith G.K., Chen Z., Webb C., Khandekar S., Yi T., Kirkpatrick R., Dul E., Jolivette L., Marino J.P., Willette R., Lee D., and Hu E. J. Pharmacol. Exp. Ther. 320 (2007) 89
7. Stavenger R.A., Cui H., Dowdell S.E., Franz R.G., Gaitanopoulos D.E., Goodman K.B., Hilfiker M.A., Ivy R.L., Leber J.D., Marino J.P., Oh H.-J., Viet A.Q., Xu W., Ye G., Zhang D., Zhao Y., Jolivette L.J., Head M.S., Semus S.F., Elkins P.A., Kirkpatrick R.B., Dul E., Khandekar S.S., Yi T., Jung D.K., Wright L.L., Smith G.K., Behm D.J., Doe C.P., Bentley R., Chen Z.X., Hu E., and Lee D. J. Med. Chem. 50 (2007) 2
8. Bamford M.J., Alberti M.J., Bailey N., Davies S., Dean D.K., Gaiba A., Garland S., Harling J.D., Jung D.K., Panchal T.A., Patt C.A., Steadman J.G., Takle A.K., Townsend J.T., Wilson D.M., and Witherington J. Bioorg. Med. Chem. Lett. 15 (2005) 3402
9. Bamford M.J., Bailey N., Davies S., Dean D.K., Francis L., Panchal T.A., Parr C.A., Sehmi S., Steadman J.G., Takle A.K., Townsend J.T., and Wilson D.M. Bioorg. Med. Chem. Lett. 15 (2005) 3407
10. Hanks S.K. Genome Biol. 4 (2003) 111
11. Sequence alignment of p70S6 K to PKAa used blastp (http://blast.ncbi.nlm.nih.gov/). The preliminary threaded model was constructed using Swiss-Pdb viewer (http://spdbv.vital-it.ch/), initial inhibitor placement, model refinement, and inhibitor docking was done using macromodel and glide programs (www.schrodinger.com).
12. Tselinskii I.V., Mel'nikova S.F., Pirogov S.V., and Sergievskii A.V. Russ. J. Org. Chem. 35 (1999) 296
13. Assay conditions are provided in the Supplementary data.
14. Andrianov V.G., and Eremeev A.V. Chem. Heterocycl. Compd. 30 (1994) 608